Abstracts tagged "rituximab and systemic lupus erythematosus (SLE)"

Abstract Number: 1573 • 2013 ACR/ARHP Annual Meeting
Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome
Sofia Dias¹, Veronica Rodriguez², Hanh Nguyen³, Charis Pericleous⁴ and David A. Isenberg⁵, ¹Internal Medicine Department 1, Hospital de Santa Maria, Lisbon, Portugal, ²Hospital Regional Universitario Carlos Haya, Malaga, Spain, ³Centre of Rheumatology. Medicine., University College of London Hospital, london, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: We were alerted to the possibility of very long term B cell depletion (BCD) in Systemic Lupus Erythematosus (SLE) by a patient treated with…
Abstract Number: 1559 • 2013 ACR/ARHP Annual Meeting
Cyclophosphamide and Rituximab Combination Treatment For Severe Systemic Lupus erythematosus is Effective and Well Tolerated
Ali Shahzad¹, Farheen Jafri², Bisharah Rizvi², Xiongce Zhao³, Meryl Waldman³ and Sarfaraz A. Hasni⁴, ¹National Institute of Arthritis, Musculoskeletal and skin diseases, NIAMS/NIH, Bethesda, MD, ²R-Research, Hamilton, NJ, ³NIDDK/NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is often complicated by resistance or partial response to initial immunosuppressive regimen and flares after initial response. Optimal management of…
Abstract Number: 1958 • 2012 ACR/ARHP Annual Meeting
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Claudia Mendoza-Pinto¹, Mario Garcia-Carrasco¹, Mario Jiménez-Hernández¹, Alma Rodríguez-Gallegos², Socorro Méndez-Martínez¹ and Aurelio Lopez-Colombo³, ¹Systemic Autoimmune Disease, HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Laboratorios Clínicos de Puebla, Puebla, Mexico, ³Research Departament, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Low bone mineral density (BMD) and osteoporosis may be significant complications in patients with systemic lupus erythematosus (SLE). Recent studies have shown that biologic therapy could…
Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Venkat Reddy¹, Sara Croca², Delia Gerona³, Inmaculada De La Torre Ortega³, David A. Isenberg⁴, Maria Leandro² and Geraldine Cambridge⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Thomas J. A. Lehman¹, Emily Baird², Anusha Ramanathan³, Risa Alperin³, Emma J. MacDermott³, Alexa B. Adams³, Laura V. Barinstein³ and Lakshmi N. Moorthy⁴, ¹Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, ²Hospital for Special Surgery, NY, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…
Abstract Number: 606 • 2012 ACR/ARHP Annual Meeting
Risk Factors Associated with Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: The Role of Rituximab
Mario Garcia-Carrasco¹, Claudia Mendoza Pinto¹, Alejandro Taboada-Cole¹, Verónica Vallejo-Ruiz², Julio Reyes-Leyva² and Aurelio Lopez-Colombo³, ¹Systemic Autoimmune Disease, HGR 36 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Laboratorio de Biología Molecular y Virología, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Hospital General de Zona No. 5, Puebla, Mexico, ³Research Departament, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune, multisystemic disease that affects women of reproductive age. Women with SLE have an increased risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].